The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.
Study Type
OBSERVATIONAL
Enrollment
10,000
Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
Peking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGVancomycin-associated acute kidney injury(VAN-AKI) occuration rate
Time frame: 1 year
VAN-AKI detection rate
Time frame: 1 year
TDM detction rate
Time frame: 1 year
0h Serum creatinine detction rate
Time frame: 1 year
48h Serum creatinine detction rate
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.